Biogen Inc Share Price - BIIB, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(NASDAQ:BIIB, BIIB)

Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.

News

24/04/12
Biogen’s multiple sclerosis drug meets primary endpoint
14/02/12
Biogen Idec to buy Stromedix in up to $563 mln deal
31/01/12
Biogen Idec Q4 earnings grow on higher MS drug sales
23/01/12
Biogen Idec wins FDA approval for MS drug label change
28/10/11
Biogen Idec reiterates earnings outlook as Q3 profits beat Street
26/10/11
Biogen Idec achieves top line results from second phase 3 study of MS drug
21/10/11
Biogen Idec reports positive phase 3 data from MS drug
09/08/11
Biogen Idec, Abbott report positive results from phase 2 MS study
11/04/11
Biogen Idec meets main goal in phase 3 study for MS drug
01/02/11
Biogen Idec reports better-than-expected fourth quarter results

All Biogen Inc News ►

Recent Sector News

Dow suffers on Greece fears, Hewlett-Packard in focus

U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
Dow points lower ahead of eurozone meeting, Facebook, Dell in focus

U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
Q1 gold demand underpinned by China, Central Banks and ETFs

Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up

Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
Facebook boosts public offering by 25%

Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
Snipp plans ambitious growth as mobile marketing takes off

Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.